Carcinoma in Situ Clinical Trial
Official title:
Phase II Pilot Study With TMX 101 in Patients With Carcinoma In Situ (CIS) Bladder Cancer
This is a Phase II pilot study to explore the effect of intravesical TMX-101 in patients with CIS bladder cancer, as assessed by histology and cytology after TMX-101 treatment.
This study is an open label, pilot study of TMX-101 in the treatment of carcinoma in situ.
TMX-101 is a new formulation of Imiquimod optimized for intravesical delivery. Imiquimod
possesses immune-stimulatory properties. TMX-101 is being developed as a potential treatment
for patients with non-invasive bladder cancer, including patients with CIS bladder cancer.
Following confirmation of CIS by histology, patients will receive weekly instillations of
TMX-101 for 6 weeks. Five to seven weeks after the last instillation, biopsies and cytology
will be performed. Response to treatment will be determined based on cytology and tissue
sample histology findings.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06022029 -
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
|
Phase 1 | |
| Recruiting |
NCT02402244 -
Project: Every Child for Younger Patients With Cancer
|
||
| Recruiting |
NCT03223753 -
Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Cancer
|
Phase 3 | |
| Completed |
NCT02039388 -
Lavage of the Uterine Cavity for the Diagnosis of Serous Tubal Intraepithelial Carcinoma
|
N/A | |
| Terminated |
NCT01200992 -
Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer
|
Phase 3 | |
| Completed |
NCT01316874 -
Intravesical AD 32 (Valrubicin) in Patients With Carcinoma in Situ (CIS) of the Bladder Who Have Failed or Have Recurrence Following Treatment With Bacillus Calmette-guerin (BCG)
|
Phase 2/Phase 3 | |
| Completed |
NCT04823871 -
Early Detection of High Grade Ovarian Cancer Using Uterine Lavage EHUD Study and Duplex Sequencing
|
N/A | |
| Recruiting |
NCT06056843 -
Handheld Ultrasound Device to Triage Women With a Positive Clinical Breast Examination by Trained Non-radiologists
|
N/A | |
| Terminated |
NCT01310803 -
Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder
|
Phase 3 | |
| Terminated |
NCT01438112 -
Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer
|
Phase 2/Phase 3 | |
| Completed |
NCT03268993 -
Effects of Avmacol® in the Oral Mucosa of Patients Following Curative Treatment for Tobacco-related Head and Neck Cancer
|
N/A | |
| Completed |
NCT04312737 -
Evaluation of in Vitro Devices on Self-collected Vaginal Swab and Urine Sample for Testing of Human Papilloma Virus
|
||
| Recruiting |
NCT02858310 -
E7 TCR T Cells for Human Papillomavirus-Associated Cancers
|
Phase 1/Phase 2 | |
| Completed |
NCT01901991 -
Localization of Nonpalpable Breast Lesions
|
N/A | |
| Completed |
NCT02217358 -
Value of Narrow Band Imaging (NBI) Endoscopy in the Early Diagnosis of Laryngeal Cancer and Precancerous Lesions
|
N/A | |
| Recruiting |
NCT05014139 -
A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)
|
Phase 1 | |
| Withdrawn |
NCT02698293 -
PDT Plus Vitamin D3 for Anal Dysplasia
|
Phase 1 | |
| Completed |
NCT03808818 -
Implementing a Virtual Tobacco Treatment for Cancer Patients in Community Oncology Practices
|
Phase 2 | |
| Completed |
NCT03182959 -
Broccoli Sprout Extract in Preventing Recurrence in Patients With Tobacco-Related Head and Neck Squamous Cell Cancer
|
Early Phase 1 |